Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
17 nov. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the...
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
16 nov. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D.,...
Abeona Therapeutics Reports Third Quarter Financial Results
15 nov. 2021 07h45 HE
|
Abeona Therapeutics Inc.
Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening Added gene therapy and biopharmaceutical industry veterans to regulatory...
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
21 oct. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D.,...
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
13 oct. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously...
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
12 oct. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as...
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
21 sept. 2021 16h01 HE
|
Abeona Therapeutics Inc.
Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board Vishwas Seshadri, Ph.D., M.B.A. to become Chief Executive Officer Brendan M. O’Malley,...
Abeona Therapeutics to Present at Upcoming Investor Conferences
07 sept. 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s...
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
10 août 2021 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr...
Abeona Therapeutics Reports Second Quarter Financial Results
28 juil. 2021 16h01 HE
|
Abeona Therapeutics Inc.
Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study Successful Type B meeting with U.S. FDA; Transpher A study will serve as the pivotal study for ABO-102 in MPS IIIA;...